EN DE
Watch Myriad Genetics Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Myriad Genetics Inc (MYGN) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Myriad Genetics Inc stock $5.60, price $5.67, that is 1.2% below the price, quality 43 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

MG Myriad Genetics Inc logo Thin data Nov 11, 2026

Myriad Genetics Inc

MYGN · US
Fairly valued, weak quality

The stock costs about what our calculation considers fair.

Low debt
Fair value $5.60 · Fairly valued
Quality 43/100
Mixed Growth (revenue 5y +8.2 %/yr in USD)
Neutral coverage
Insiders bought $27,675 (6M) · sold $66,900
Loss-making · -16.1% net margin (TTM) · excl. goodwill write-downs -15.1%
Negative free cash flow
Trails peers (4/11)
Narrow moat 14/100
Thin data
Estimate
Watch Myriad Genetics Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$36.66 $2.86 Fair Value $5.60 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.

How to read this chart

60‑month range $2.86 – $36.66 · fair‑value band $4.20 – $7.01 · the $5.67 price screens above the $5.60 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 11, 2026.

Follow Myriad Genetics in your weekly email

Every Wednesday you see whether Myriad Genetics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics.

Show moreShow less

It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.

In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions.

It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children's Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

Stock analysis

Myriad Genetics Inc (MYGN) currently trades at $5.67, while our estimate is $5.60, so the stock looks roughly fairly valued today (gap 1.3%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $4.20 (bear) to $7.01 (bull), the price of $5.67 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Myriad Genetics Inc reported revenue of $825M in FY2025 versus $691M in FY2021, a compound +4.5%/yr. Reported net income was −$366M in FY2025.

Key figures

Market cap $538M Small · P/S ratio 0.68 · EPS (TTM) $−1.35 · Net margin −16.1% · Return on equity −40.2% · Return on assets (EBIT) −14.0% (5-year average) · Operating margin −19.7% · Revenue (TTM) $804M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 14 out of 100 (medium confidence).

What moves the price

The share trades about 28% below its 52-week high and 98% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −11% fair-value upside, at −1%, MYGN screens cheaper than that median.

Fair Value

Bear $4.20 Fair Value $5.60 Bull $7.01
Price $5.67 · Downside -1.2%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 43/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 38
How much profit the company makes from its sales and capital
Quality Growth 32
Are margins and returns getting better?
Cashflow 7
Do the profits arrive as real cash?
Financial strength 58
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 7
How calm the share price moves, does not count
Price momentum 62
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 39
Distance to the 52-week high, does not count
New shares 50
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director bought shares worth $27,675, on May 14, 2026. Over the same period, one person sold shares worth $66,900.

  • SaleRashmi KumarDirector15,000 shares at $4.46$66,900Jun 8, 202610b5-1 plan
  • BuyPaul BisaroDirector7,500 shares at $3.69$27,675May 14, 2026
  • BuySamraat S. RahaPresident and CEO, Director40,000 shares at $5.00$200,000Mar 9, 2026
  • BuyS. Louise PhanstielDirector104,507 shares at $4.73$494,548Feb 27, 2026

Plus 16 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 16/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−1.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.2%
Start year 2020 (pandemic). Over 10 years: +1.3% a year
Revenue growth 30 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−35.0% (2020) → −8.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch MYGN, get fair value alerts →

Recent news

News mood ⓘNews mood, the average tone of recent news (94 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Neutral
Recent news coverage is roughly neutral, about typical for how stocks are covered.

Compare Myriad Genetics Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 149 stocks

Beats the industry median on 4/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 43 · Below median
Fair Value upside −1.2% · Above median
Profitability
Return on assets −51.8% · Bottom 25%
Net margin (12 months) −16.1% · Bottom 25%
Operating margin (12 months) −19.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −1.5% · Below median
Balance sheet
Debt / equity 0.33× · Above median

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/B 1.46× · Cheaper than median
P/S (12 months) 0.67× · Cheapest 25%
PEG 1.40× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)32 · sector 12
FUTURE (revenue growth)0 · sector 40
PAST (return on equity)0 · sector 7
HEALTH (low debt)84 · sector 95
DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
WuXi AppTec Co 603259 ¥150.30 ¥165.32 +10% vs MYGN
Illumina, Inc ILMN $214.91 $234.44 +9% vs MYGN
IQVIA Holdings IQV $275.15 $299.58 +9% vs MYGN
Thermo Fisher Scientific Inc TMO $718.20 $686.04 −4% vs MYGN
Danaher Corporation DHR $236.11 $209.18 −11% vs MYGN
IDEXX Laboratories, Inc IDXX $696.64 $496.48 −29% vs MYGN
Mettler-Toledo International Inc MTD $1,751 $655.06 −63% vs MYGN
Agilent Technologies, Inc A $177.88 $64.53 −64% vs MYGN
Lonza Group LONN CHF 661.00 CHF 153.50 −77% vs MYGN
Waters Corporation WAT $475.52 $91.26 −81% vs MYGN

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Myriad Genetics Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Myriad Genetics Inc Fair Value". https://www.fairvalue-calculator.com/stock/MYGN

Frequently asked questions

Is Myriad Genetics Inc (MYGN) overvalued or undervalued?
As of Nov 11, 2026, our estimate of fair value is $5.60 versus a price of $5.67, about 1% lower (fairly valued).
What is the fair value of MYGN?
Our estimate for Myriad Genetics Inc is $5.60 (as of Nov 11, 2026), built from audited fundamentals. The current price: $5.67.
What is the quality score of MYGN?
Myriad Genetics Inc has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Myriad Genetics Inc (MYGN)?
Our calculated price target is the estimate of $5.60 (as of Nov 11, 2026). Cautious scenario $4.20, optimistic scenario $7.01. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Myriad Genetics Inc stock forecast for 2026?
Our estimate puts fair value at $5.60, about 1% lower versus a price of $5.67 (fairly valued). Cautious scenario $4.20, optimistic scenario $7.01. The calculation is refreshed regularly with new filings.
What is the revenue of Myriad Genetics Inc (MYGN)?
Myriad Genetics Inc reported trailing-twelve-month revenue of about $804M (latest available figure, as of Nov 11, 2026).
What is the intrinsic value of Myriad Genetics Inc (MYGN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Myriad Genetics Inc it is $5.60 per share (as of Nov 11, 2026), against a price of $5.67.
Is Myriad Genetics Inc stock overvalued or undervalued in 2026?
As of Nov 11, 2026, MYGN trades above its calculated fair value: price $5.67, fair value $5.60, a gap of about −1% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MYGN?
No. The price is what the market pays today ($5.67); the fair value is what the company's own numbers justify ($5.60). For Myriad Genetics Inc the two are $0.0700 per share apart. That gap is exactly why we show both numbers side by side.
How much is Myriad Genetics Inc worth?
The market values Myriad Genetics Inc at about $538M (market capitalisation, as of Nov 11, 2026). Per share that is $5.67; our models calculate a fair value of $5.60 per share.
What do the bullish and bearish scenarios say about MYGN?
Our models span a range for Myriad Genetics Inc: cautious scenario $4.20, base $5.60, optimistic $7.01 per share (as of Nov 11, 2026, price $5.67). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of MYGN?
The PEG ratio of Myriad Genetics Inc is 1.40 (P/E divided by earnings growth, as of Nov 11, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Myriad Genetics Inc (MYGN)?
Balance-sheet figures for Myriad Genetics Inc (as of Nov 11, 2026): return on equity −40.2%, debt of 0.33 per unit of equity. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is MYGN from its 52-week high?
Myriad Genetics Inc trades at $5.67, about 28% below its 52-week high of $7.91 and 98% above the low of $2.86 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $5.60 is for.
Which stocks are comparable to Myriad Genetics Inc?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, IDEXX Laboratories, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Myriad Genetics Inc stock attractive at the current price?
The data as of Nov 11, 2026: price $5.67, calculated fair value $5.60 (−1%), Quality Score 43/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Myriad Genetics Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Myriad Genetics Inc (MYGN)?
The closing price on Nov 10, 2026 was $5.67. Our estimate is $5.60, about 1% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Myriad Genetics Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Myriad Genetics Inc

How large is the market capitalisation of Myriad Genetics Inc (MYGN)?
The market capitalisation of Myriad Genetics Inc is $538M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Myriad Genetics Inc (MYGN)?
The price-to-sales ratio of Myriad Genetics Inc is 0.68 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Myriad Genetics Inc (MYGN)?
Earnings per share at Myriad Genetics Inc are $−1.35. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Myriad Genetics Inc (MYGN)?
The net margin of Myriad Genetics Inc is −16.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Myriad Genetics Inc (MYGN)?
The return on equity (ROE) of Myriad Genetics Inc is −40.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Myriad Genetics Inc (MYGN)?
On an EBIT basis the return on assets of Myriad Genetics Inc is −14.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Myriad Genetics Inc (MYGN)?
The operating margin of Myriad Genetics Inc is −19.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Myriad Genetics Inc (MYGN)?
Revenue at Myriad Genetics Inc is growing −1.5% versus a year earlier (3y avg +6.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Myriad Genetics Inc (MYGN) generate?
The free cash flow of Myriad Genetics Inc is −$25.6M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Myriad Genetics Inc (MYGN) carry?
The net debt of Myriad Genetics Inc is $60.2M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Myriad Genetics Inc in the live analysis

One click puts Myriad Genetics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.